We won’t restrict for that at the beginning, but we will measure for it upfront. So, we will look — if it will be another way to enhance clinical benefit by restricting the population to stop expressing tumors for it, we may have more broad activity independent of the biomarker selection. So, we’ll start broad, and then we will assess and then decide if we need to exclude or enrich for the tumors.
Matt Phipps: Got it. And then on the BCMA program, do you guys have evidence yet, I can’t — I don’t think this is a bit of kind of treating a multi-mile only cell line that relapsed or grew out of previous BCMA therapy, exposure was something maybe that’s kind of commercial or late stage? And I guess, why not go after different like GPRC5D or maybe a dual targeting construct, just given how entrenched BCMA therapies are becoming?
Jennifer Buell: Matt, BCMA therapy certainly are competitive. I hear that we’re seeing some remarkable progress with some of the more modern BCMA therapies, including very high response rate. But there is a continued problem and we have Marcellus Mouse on our Scientific Advisory Board. And what we see is that patients continuously progress on BCMA and 2/3 of them still express the BCMA antigen. So there does appear to be a challenge with respect to durability of response in the patients despite the high response rates. And we also still see challenges and access for those patients, and both of which I think that the iNKT product can address. We we’ve been able to demonstrate really robust scalability with our manufacturing capabilities, and that would certainly to our ability to enable broader access to a BCMA We’ve also armored our BCMA with IL-15.
And we have conducted and we presented it SITC and I’ll share that poster with you. We did present data that actually demonstrated superior antitumor immunity using our IL-15 BCMA CAR iNKT compared to what’s commercially available right now. That program due to its competitive nature has — we have prioritized that program and we’ve announced that previously in order to be really selective with opportunities that we believe can bring significant value creation even sooner. Now the BCMA program is very exciting for us in a program that we’re committed to advancing because of the reasons I mentioned previously, it is a program that we would contemplate strategic collaborations for as well, and we’ve been embarked in discussions predominantly with groups who actually need a degeneration BCMA that is more accessible and sustainable compared to what’s available right now.
Operator: I would now like to turn the call over to Jenn Buell, CEO, for closing remarks.
Jennifer Buell: Thank you very much, operator. It was a pleasure to be with you all today and looking forward to speaking with you at AACR. Thank you again. Bye-bye.
Operator: Thank you, ladies and gentlemen. This does conclude today’s call. Thank you for your participation. You may now disconnect.
